Highlander Health

Highlander Health’s Co-founder Amy Abernethy will be speaking at the Forbes Healthcare Summit on December 4th. The event brings together top leaders across the health care industry to give insight into the entrepreneurship, investment and new thinking that's driving the future of health care. Amy will be discussing the complex challenges facing hospitals and health care systems today and how health care leaders can leverage the latest technology innovations for improved patient care. Amy will be joining a panel of industry experts including Michael J. Alkire, President & Chief Executive Officer, Premier Inc. and Karen DeSalvo, M.D., M.P.H., Chief Health Officer, Google. She’ll also discuss how Highlander Health is working with leading academic institutions, Duke-Margolis Institute for Health Policy, Baylor Scott & White Health Research Institute, and Memorial Sloan Kettering Cancer Center, to improve clinical trial innovation and evidence generation. It is sure to be a thought-provoking day with industry leaders. Join us -? https://bit.ly/4fvhM8k #ForbesHealth #clinicaltrials

Highlander Health’s Co-founder Amy Abernethy was honored to participate in the Milken Institute’s Future of Health Summit 2024 to discuss the transformative advancements in clinical research. The panel explored how innovations are accelerating research speed and precision, and how we can tackle barriers to modernizing clinical trials and enhancing clinician engagement in research. The breakthroughs in technology and the rise of precision medicine hold tremendous potential to offer patients more tailored and effective treatments. Amy shared at the event: "From an operations perspective I think artificial intelligence is really playing a role but one of the things I would say is for the technology companies you still need to say prove it, prove the fact that this solution is actually going to work and its not going to erode the quality of the study, its conduct or the output of the results so that piece is very important. The other side of it is learning to work with technology companies. Technology companies don't want to build solutions that aren't needed or are off target.” Thank you to Amy’s fellow panelists for a thought provoking discussion: Mark McClellan, Janice Chang, Owen Garrick, MD, Ann Meeker-O'Connell and Robert Metcalf. #MIHealthSummit

Highlander Health Co-Founder Amy Abernethy will join a panel of esteemed colleagues at the CNS Summit 2024 on Nov. 11th to discuss how technology enhancements can impact evidence generation and empower health care professionals. The panel, “Predicting the Future: Pharma Panel,” will discuss how improving the design and implementation of clinical trials to ensure better representation will lead to improved patient outcomes. Amy will share her vision for the future and how Highlander Health plans to break down silos and effectively translate clinical trial results across the health care ecosystem. We hope you can join us at the CNS Summit 2024 during its 15th anniversary, November 10-13 in Boston!” #CNSSummit2024 #clinicaltrials

Highlander Health Co-founder Amy Abernethy spoke with MedCity News regarding her career journey — which has spanned across Duke University, Verily and the FDA— as well as why she founded Highlander Health with longtime colleague Brad Hirsch. Amy shares more details behind the specifics of Highlander Health’s newly announced collaborations with Duke-Margolis Institute for Health Policy, Baylor Scott & White Health Research Institute, and Memorial Sloan Kettering Cancer Center. In addition, she explains how Highlander Health Institute and Highlander Health Partners plan to take a double pronged approach to tackling clinical trial innovation and evidence generation. “In reality, many of these questions that technology seems like it can help with are still untested and the how to is unknown. As well as many stakeholders who have to believe and act as buyers don’t have the confidence to know what works and what doesn’t and what regulators will trust,” she explained. You can hear the podcast interview here -https://lnkd.in/geSEjUJ2 #clinicaltrials #evgen?

Highlander Health will attend Venture Dallas on October 30, 2024. Co-founders Brad Hirsch and Amy Abernethy will join Nicole Small of Lyda Hill Philanthropies to discuss “Revolutionizing Healthcare: Advancing Clinical Trial Innovation in North Texas.” They will discuss how they have recently joined efforts to fund grants with leading academic institutions to simplify clinical trials and innovate the potential of real-world data. The trio will also examine the Dallas eco-system’s impact on health care and the benefits of being headquartered in the region. Learn more here https://lnkd.in/gZq7jXeE? #VentureDallas #ClinicalTrials

Today, Highlander Health Co-founder Amy Abernethy took the stage at HLTH Inc. in Las Vegas with Joaquin Duato, Johnson & Johnson Chairman & CEO. They discussed their shared passion about utilizing science and technology to solve some of the biggest health care challenges of our time. During the fireside chat they discussed lots of topics, including how curing cancer is considered the ultimate health moonshot. Both agreed that getting treatments approved isn’t enough – we also need them to be widely adopted. They also touched on cardiology and the crucial role technology plays in all phases of health care. The siloed approach of healthcare is not sustainable, and data needs to be easily shared across drug development, med tech and digital health. Amy shared more about Highlander Health’s partnerships to simplify clinical trials and innovate the potential of real-world data. “We want to understand what approaches work across settings, coalesce stakeholders, and embrace the evolution happening in the market right now,” she said. The pair dove into leadership roles as well and the exciting future ahead for health care if we dare to be bold. Thanks for having us #HLTH24

We are thrilled to announce our first collaborations with Duke-Margolis Institute for Health Policy, Baylor Scott & White Health Research Institute, and Memorial Sloan Kettering Cancer Center to optimize clinical research. Joined by Lyda Hill Philanthropies, Highlander Health Institute will support a portfolio of projects at these esteemed institutions to gain insights and create innovation to simplify clinical trials and maximize the potential of real-world data. Today, co-founder Amy Abernethy spoke at the STAT Summit and highlighted these inaugural partnerships. Unlike other technological advances, the cost and complexity of clinical trials have worsened over time. We need new innovative approaches to trial design, data usage, and conduct. Amy explained how the Highlander Health Institute will create learning labs and pressure test new approaches.?You can read more here - https://lnkd.in/gc7_Zs6j #ClinicalTrials #RealWorldData #ClinicalResearch

Highlander Health Cofounder Amy Abernethy spoke with Nature Magazine regarding the potential of AI in clinical trials and evidence generation. In a rapidly evolving clinical landscape with increasingly complex clinical trials, AI and machine learning can provide streamlined solutions that bring new therapies to patients in a more efficient and cost effective way. However, there are still many challenges ahead and we need new solutions that combine traditional and real-world approaches. Amy shared Highlander Health’s plans to advance a learning healthcare system, taking data from clinical research and everyday patient care and applying this continually to improve patient treatment, getting people the medicines they need faster. You can read more here - https://lnkd.in/gsYKNDEt #AI #RealWorldData #ClinicalTrials

We are excited to announce that Highlander Health Cofounder Amy Abernethy will be joining STAT as a speaker for the #STATSummit on Oct. 17th focusing on the future of medicine. She’ll be speaking with Matthew Herper about how we develop new approaches to evidence generation that combine traditional and real-world capabilities, streamline the research process, and unlock currently untapped capacity. The development of new treatments relies on two types of data: information about basic biology, used to invent experimental medicines, and new ways to understand whether those potential treatments are safe and effective. Amy will share her vision for how we can significantly shorten the timeline of getting treatments to people who need them, and the role Highlander Health plans to play in driving this long overdue change. We hope you can join us in person or virtually: https://lnkd.in/gQj2wZEw

At ESMO - European Society for Medical Oncology, Highlander Health Cofounder Amy Abernethy presented on the main stage with Professor Jakob Nikolas Kather from Dresden, on “How AI will Transform Cancer Care.”? The pair discussed how AI solutions are quickly translating to meaningful biomarkers ready for use in the clinic, novel drug discovery, and efficiencies in the clinic. Leveraging progressively more complex multimodal datasets, sophisticated algorithms can predict the response probability for a certain patient to a certain treatment, and ease complex decision-making for oncologists. However, in order to scale AI in oncology, we need: speedy, streamlined evaluation of algorithms; regulatory clarity; and, practical education for clinicians. The team left Barcelona energized, and hopeful that AI will help transition the many new innovative treatments to personalized application in the clinic. You can read the full Annals of Oncology paper here - https://lnkd.in/gC3DR9db #ESMO24